Rosuvastatin Tablet, Film Coated
Product Images NDC 70518-4296

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 70518-4296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a description of a prescription medication called Rosuvastatin 20 mg tablets. It comes in a quantity of 45 tablets. The medication is manufactured by ScieGen in Hauppauge, NY. The packaging includes the NDC numbers for original and repackaged products, storage instructions, and a note to keep out of reach of children. Directions for use are provided on the package insert.*
FDA Label Image

Figure-01 (Figure 1)

Figure-01 (Figure 1)
This text provides data on a study comparing the effectiveness of a certain treatment (RSV) with a placebo. The numbers represent the number at risk and the years in the study for each group. The RSV group had a higher number at risk compared to the placebo group. The study measured the outcomes over a period of time and provides information on the effectiveness of the treatment compared to the placebo.*
FDA Label Image

Figure-02 (Figure 2)

Figure-02 (Figure 2)
This is a statistical analysis comparing the effect of Rosuvastatin 20 mg versus Placebo 20 mg in a total of 8901 participants. The results show hazard ratios and confidence intervals for various endpoints including the primary endpoint (MCE), cardiovascular death, nonfatal stroke, nonfatal MI, and hospitalized unstable angina. The analysis also includes arterial revascularization rates. The study indicates significant differences favoring Rosuvastatin in reducing the primary endpoints, cardiovascular death, stroke, and MI. Additionally, the study outlines the definition of cardiovascular death to include fatal events such as stroke, sudden death, and other causes related to cardiovascular issues.*
FDA Label Image

Figure-02 (Figure 3)

Figure-02 (Figure 3)
FDA Label Image

Structural Formula (Rosuvastatin Str)

Structural Formula (Rosuvastatin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.